Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Jiang‐Jiang Qin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-8559-616X; OpenAlex author ID A5017743504. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
23
Papers, trials and grants by year

2018: 2 papers · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 10

  1. Targeting CTGF+ cancer-associated fibroblasts disrupts tumor-stroma crosstalk in pancreatic ductal adenocarcinoma. Co-author DOI 10.1073/pnas.2535905123↗
  2. Morusin Suppresses Pancreatic Cancer Cell Proliferation and Migration by Targeting SLC6A12 to Inhibit NF-κB and β-catenin Signaling Pathways. Last author DOI 10.2174/0115748928376279250613051117↗
  3. IFN-γ-driven UBE2D3 upregulation impairs antigen presentation pathways and anti-tumor immunity in pancreatic cancer. Last author DOI 10.1038/s41467-025-65762-4↗
  4. Expanding the ubiquitin code in pancreatic cancer. Last author DOI 10.1016/j.bbadis.2023.166884↗
  5. Characteristics of Gut Microbiome in the Murine Model of Pancreatic Cancer with Damp-Heat Syndrome. Co-author DOI 10.3390/biomedicines12102360↗
  6. Targeting E2 ubiquitin-conjugating enzyme UbcH5c by small molecule inhibitor suppresses pancreatic cancer growth and metastasis. Last author DOI 10.1186/s12943-022-01538-4↗
  7. Integrative analysis reveals clinically relevant molecular fingerprints in pancreatic cancer. Co-author DOI 10.1016/j.omtn.2021.06.015↗
  8. Dual roles and therapeutic potential of Keap1-Nrf2 pathway in pancreatic cancer: a systematic review. Co-author DOI 10.1186/s12964-019-0435-2↗
  9. Discovery and Characterization of Dual Inhibitors of MDM2 and NFAT1 for Pancreatic Cancer Therapy. First author DOI 10.1158/0008-5472.can-17-3939↗
  10. Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Co-author DOI 10.3389/fphar.2018.00005↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenyan Yang · 3 shared papers, 2024–2026 · strength 0.84
  2. Shiqun Wang · 3 shared papers, 2024–2026 · strength 0.77
  3. Weidong Zhang · 3 shared papers, 2022–2026 · strength 0.64
  4. Xin Luan · 2 shared papers, 2025–2026 · strength 0.49
  5. Weidong Zhang · 2 shared papers, 2019–2024 · strength 0.42
  6. Xiangdong Cheng · 2 shared papers, 2019–2022 · strength 0.29
  7. Simin Qi · 2 shared papers, 2021–2022 · strength 0.26
  8. Yiwen Shen · 1 shared paper, 2026 · strength 0.26
  9. Qian Xiang · 1 shared paper, 2024 · strength 0.23
  10. Yangbo Tong · 1 shared paper, 2024 · strength 0.23
  11. Yuhua Zhang · 1 shared paper, 2024 · strength 0.23
  12. Ruiwen Zhang · 2 shared papers, 2018 · strength 0.18
  13. Xiaoqing Guan · 1 shared paper, 2022 · strength 0.15
  14. Wenjuan Yin · 1 shared paper, 2022 · strength 0.15
  15. Zhouyu Ning · 1 shared paper, 2021 · strength 0.11
  16. Libin Song · 1 shared paper, 2021 · strength 0.11
  17. Shengli Li · 1 shared paper, 2021 · strength 0.11
  18. Lanyun Feng · 1 shared paper, 2021 · strength 0.11
  19. Bo Zhang · 1 shared paper, 2021 · strength 0.11
  20. Luming Liu · 1 shared paper, 2021 · strength 0.11
  21. John K Buolamwini · 1 shared paper, 2018 · strength 0.10
  22. Hemantkumar S. Deokar · 1 shared paper, 2018 · strength 0.10
  23. Wei Wang · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.